Journal
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
Volume 33, Issue 5, Pages 658-666Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JCP.0b013e3182979d32
Keywords
MDMA; 3,4-methylenedioxymethamphetamine; norepinephrine; doxazosin; alpha(1)-adrenergic receptor
Categories
Funding
- Swiss National Science Foundation [323230_126231]
- Swiss National Science Foundation (SNF) [323230_126231] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Preclinical studies implicate a role for alpha(1)-noradrenergic receptors in the effects of psychostimulants, including 3,4-methylenedioxymethamphetamine (MDMA, ecstasy''). The present study evaluated the effects of the alpha(1)-noradrenergic receptor antagonist doxazosin on the acute pharmacodynamic and pharmacokinetic response toMDMA in 16 healthy subjects. Doxazosin (8 mg/d) or placebo was administered for 3 days before MDMA (125 mg) or placebo using a randomized, double-blind, placebo-controlled, 4-session, crossover design. Doxazosin reduced MDMA-induced elevations in blood pressure, body temperature, and moderately attenuated positive mood but enhanced tachycardia associated with MDMA. The results indicate that alpha(1)-adrenergic receptors contribute to the acute cardiostimulant and to a minor extent possibly also to the thermogenic and euphoric effects of MDMA in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available